NYSE:IQV - New York Stock Exchange, Inc. - US46266C1053 - Common Stock - Currency: USD
150.68
-5.45 (-3.49%)
The current stock price of IQV is 150.68 USD. In the past month the price decreased by -0.16%. In the past year, price decreased by -34.82%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
TMO | THERMO FISHER SCIENTIFIC INC | 19.59 | 161.92B | ||
DHR | DANAHER CORP | 26.39 | 140.71B | ||
A | AGILENT TECHNOLOGIES INC | 21.74 | 32.91B | ||
MTD | METTLER-TOLEDO INTERNATIONAL | 29.09 | 24.53B | ||
WAT | WATERS CORP | 30.14 | 21.36B | ||
WST | WEST PHARMACEUTICAL SERVICES | 32.51 | 15.51B | ||
ILMN | ILLUMINA INC | 24.11 | 12.71B | ||
TEM | TEMPUS AI INC | N/A | 11.92B | ||
RVTY | REVVITY INC | 19.62 | 11.62B | ||
ICLR | ICON PLC | 10.24 | 11.60B | ||
QGEN | QIAGEN N.V. | 18.31 | 9.10B | ||
AVTR | AVANTOR INC | 13.17 | 9.06B |
IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. The company is headquartered in Durham, North Carolina and currently employs 88,000 full-time employees. The company went IPO on 2013-05-09. Its segments include Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides mission-critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, and provides outsourced clinical research and clinical trial-related services. The Contract Sales & Medical Solutions segment provides healthcare provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company offers a set of strategic and implementation consulting services, including advanced analytics and commercial processes outsourcing services.
IQVIA HOLDINGS INC
2400 Ellis Road
Durham NORTH CAROLINA 27703 US
CEO: Ari Bousbib
Employees: 88000
Phone: 19199982000
The current stock price of IQV is 150.68 USD. The price decreased by -3.49% in the last trading session.
The exchange symbol of IQVIA HOLDINGS INC is IQV and it is listed on the New York Stock Exchange, Inc. exchange.
IQV stock is listed on the New York Stock Exchange, Inc. exchange.
30 analysts have analysed IQV and the average price target is 219.17 USD. This implies a price increase of 45.45% is expected in the next year compared to the current price of 150.68. Check the IQVIA HOLDINGS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
IQVIA HOLDINGS INC (IQV) has a market capitalization of 26.57B USD. This makes IQV a Large Cap stock.
IQVIA HOLDINGS INC (IQV) currently has 88000 employees.
IQVIA HOLDINGS INC (IQV) has a support level at 149.92 and a resistance level at 156.14. Check the full technical report for a detailed analysis of IQV support and resistance levels.
The Revenue of IQVIA HOLDINGS INC (IQV) is expected to grow by 4.18% in the next year. Check the estimates tab for more information on the IQV EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
IQV does not pay a dividend.
IQVIA HOLDINGS INC (IQV) will report earnings on 2025-07-21, before the market open.
The PE ratio for IQVIA HOLDINGS INC (IQV) is 13.33. This is based on the reported non-GAAP earnings per share of 11.3 and the current share price of 150.68 USD. Check the full fundamental report for a full analysis of the valuation metrics for IQV.
The outstanding short interest for IQVIA HOLDINGS INC (IQV) is 1.61% of its float. Check the ownership tab for more information on the IQV short interest.
ChartMill assigns a fundamental rating of 5 / 10 to IQV. While IQV belongs to the best of the industry regarding profitability, there are concerns on its financial health.
Over the last trailing twelve months IQV reported a non-GAAP Earnings per Share(EPS) of 11.3. The EPS increased by 9.71% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 8.61% | ||
ROA | 4.88% | ||
ROE | 22.32% | ||
Debt/Equity | 2.19 |
ChartMill assigns a Buy % Consensus number of 80% to IQV. The Buy consensus is the average rating of analysts ratings from 30 analysts.
For the next year, analysts expect an EPS growth of 7.43% and a revenue growth 4.18% for IQV